Hikma Pharmaceuticals partners with Emergent BioSolutions to expand access to KLOXXADO nasal spray
Hikma Pharmaceuticals PLC has announced an exclusive partnership with Emergent BioSolutions to commercialise KLOXXADO (naloxone HCl) nasal spray 8 mg in the United States and ... Read More
FDA approves first generic liraglutide injection for Type 2 diabetes treatment
In a significant milestone for diabetes care, the U.S. Food and Drug Administration (FDA) has approved the first generic equivalent of liraglutide injection, a glucagon-like ... Read More
FDA approval for Zurnai Auto-Injector: A new weapon in the fight against opioid overdose
In a major development in the battle against the opioid epidemic, Purdue Pharma’s Zurnai Auto-Injector has been granted approval by the US Food and Drug ... Read More
Shahin Fesharaki appointed as Lupin Global Chief Scientific Officer
Indian pharmaceutical company Lupin announced that Dr. Shahin Fesharaki has been appointed as Global Chief Scientific Officer who will handle global research and development works ... Read More
Glenmark gets marketing approval for Ryaltris in 13 European countries
Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13 countries across the European Union (EU) and ... Read More
Bio-Thera, Hikma Pharmaceuticals sign $150m licensing deal for BAT2206
Chinese biopharma company Bio-Thera Solutions has signed a commercialization and license deal worth up to $150 million with Hikma Pharmaceuticals to commercialize the former’s BAT2206. ... Read More